Weekly docetaxel monotherapy for advanced gastric or esophagogastric junction cancer. Results of a phase II study in elderly patients or patients with impaired performance status

K. Abbrederis, S. Lorenzen, L. Fischer von Weikersthal, U. Vehling-Kaiser, T. Schuster, N. Rothling, C. Peschel, F. Lordick

Research output: Contribution to journalReview articlepeer-review

12 Scopus citations

Abstract

Background: Three-weekly docetaxel is active in patients with advanced esophagogastric cancer but myelosuppression may make this schedule unsuitable for some patient groups such as elderly, pretreated, or poor performance status patients. Patients and methods: Eligible patients were chemonaive with Karnofsky index ≤70% and/or had received prior platinum-based chemotherapy. Docetaxel 35 mg/m2 was administered on days 1, 8, 15, 22, 29, and 36 of a 49-day cycle. The primary endpoint was disease stabilization rate. Results: Of 46 patients (median age, 68.5 years; 47% ≥70 years) included, 87% had Karnofsky index ≤70 and 50% had prior treatment. The safety profile was acceptable. Principal grade 3/4 toxicities were leukopenia (9%) and fatigue (14%). Fifteen patients experienced no progression for ≥100 days (disease stabilization rate: 36%). Overall response rate was 9%; median overall survival was 7.0 months. Conclusions: Weekly docetaxel was well tolerated and achieved disease stabilization in one-third of difficult-to-treat patients.

Original languageEnglish
Pages (from-to)84-90
Number of pages7
JournalCritical Reviews in Oncology/Hematology
Volume66
Issue number1
DOIs
StatePublished - Apr 2008
Externally publishedYes

Keywords

  • Chemotherapy
  • Docetaxel
  • Elderly patients
  • Gastric cancer
  • Performance status

Fingerprint

Dive into the research topics of 'Weekly docetaxel monotherapy for advanced gastric or esophagogastric junction cancer. Results of a phase II study in elderly patients or patients with impaired performance status'. Together they form a unique fingerprint.

Cite this